These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
261 related articles for article (PubMed ID: 8383579)
1. Pathologic correlates of prognosis in lymph node-positive breast carcinomas. Clayton F; Hopkins CL Cancer; 1993 Mar; 71(5):1780-90. PubMed ID: 8383579 [TBL] [Abstract][Full Text] [Related]
2. Pathologic correlates of survival in 378 lymph node-negative infiltrating ductal breast carcinomas. Mitotic count is the best single predictor. Clayton F Cancer; 1991 Sep; 68(6):1309-17. PubMed ID: 1651805 [TBL] [Abstract][Full Text] [Related]
4. Comparative predictive value of three prognostic markers--S-phase fraction, PCNA and Mitotic count on axillary lymph node metastasis in carcinoma breast. Pervez S; Khan MN; Nasir MI J Ayub Med Coll Abbottabad; 2007; 19(1):3-5. PubMed ID: 17867469 [TBL] [Abstract][Full Text] [Related]
5. Prognosis in stage II (T1N1M0) breast cancer. Rosen PP; Saigo PE; Braun DW; Weathers E; Kinne DW Ann Surg; 1981 Nov; 194(5):576-84. PubMed ID: 6271083 [TBL] [Abstract][Full Text] [Related]
6. Staging in the therapy of cancer of the breast. Silverberg SG Am J Clin Pathol; 1975 Dec; 64(6):756-63. PubMed ID: 173178 [TBL] [Abstract][Full Text] [Related]
7. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer. Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899 [TBL] [Abstract][Full Text] [Related]
8. The pathological findings of breast cancer in patients surviving 25 years after radical mastectomy. Dawson PJ; Ferguson DJ; Karrison T Cancer; 1982 Nov; 50(10):2131-8. PubMed ID: 6290024 [TBL] [Abstract][Full Text] [Related]
9. Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes. Rouzier R; Extra JM; Klijanienko J; Falcou MC; Asselain B; Vincent-Salomon A; Vielh P; Bourstyn E J Clin Oncol; 2002 Mar; 20(5):1304-10. PubMed ID: 11870173 [TBL] [Abstract][Full Text] [Related]
10. Reappraisal of internal mammary node metastases as a prognostic factor in patients with breast cancer. Noguchi M; Ohta N; Koyasaki N; Taniya T; Miyazaki I; Mizukami Y Cancer; 1991 Nov; 68(9):1918-25. PubMed ID: 1655229 [TBL] [Abstract][Full Text] [Related]
11. Treatment and survival of female patients with nonpalpable breast carcinoma. Tinnemans JG; Wobbes T; Holland R; Hendriks JH; Van der Sluis RF; De Boer HH Ann Surg; 1989 Feb; 209(2):249-53. PubMed ID: 2537064 [TBL] [Abstract][Full Text] [Related]
12. Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years. Rosen PP; Groshen S; Saigo PE; Kinne DW; Hellman S J Clin Oncol; 1989 Sep; 7(9):1239-51. PubMed ID: 2549203 [TBL] [Abstract][Full Text] [Related]
13. Lymph node metastases versus DNA ploidy as prognostic factors for invasive ductal carcinoma of the breast. Noguchi M; Taniya T; Ohta N; Koyasaki N; Miyazaki I; Mizukami Y Breast Cancer Res Treat; 1991 Sep; 19(1):23-31. PubMed ID: 1661623 [TBL] [Abstract][Full Text] [Related]
14. Occult metastases in axillary lymph nodes as a predictor of survival in node-negative breast carcinoma with long-term follow-up. Reed W; Bøhler PJ; Sandstad B; Nesland JM Breast J; 2004; 10(3):174-80. PubMed ID: 15125740 [TBL] [Abstract][Full Text] [Related]
15. Axillary lymph node dissection in pT1 breast cancer: a retrospective analysis of 315 patients and review of the literature. Witt A; Obwegeser R; Auerbach L; Tempfer C; Yavuz D; Kubista E Wien Klin Wochenschr; 2002 Jun; 114(10-11):387-90. PubMed ID: 12708092 [TBL] [Abstract][Full Text] [Related]
16. [Lobular invasive breast cancer prognostic factors: About 940 patients]. Jauffret C; Houvenaeghel G; Classe JM; Garbay JR; Giard S; Charitansky H; Cohen M; Bélichard C; Faure C; Darai É; Hudry D; Azuar P; Villet R; Gimbergues P; Tunon de Lara C; Martino M; Coutant C; Dravet F; Chauvet MP; Chéreau Ewald E; Penault-Llorca F; Goncalves A; Lambaudie É Gynecol Obstet Fertil; 2015 Nov; 43(11):712-7. PubMed ID: 26482833 [TBL] [Abstract][Full Text] [Related]
17. Prognostic value of mitotic counts in axillary node negative breast cancer patients with predominantly well-differentiated tumours. Fiets WE; Bellot FE; Struikmans H; Blankenstein MA; Nortier JW Eur J Surg Oncol; 2005 Mar; 31(2):128-33. PubMed ID: 15698727 [TBL] [Abstract][Full Text] [Related]
18. Relationship of necrosis and tumor border to lymph node metastases and 10-year survival in carcinoma of the breast. Carter D; Pipkin RD; Shepard RH; Elkins RC; Abbey H Am J Surg Pathol; 1978 Mar; 2(1):39-46. PubMed ID: 205137 [TBL] [Abstract][Full Text] [Related]
19. [Proliferation index and its prognostic value in invasive ductal breast carcinoma]. Falco M Ann Acad Med Stetin; 2009; 55(1):22-30. PubMed ID: 20349588 [TBL] [Abstract][Full Text] [Related]
20. The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years. Reed W; Hannisdal E; Boehler PJ; Gundersen S; Host H; Marthin J Cancer; 2000 Feb; 88(4):804-13. PubMed ID: 10679650 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]